FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Closing the gap: How new screening interventions could reduce inequalities in... July 5, 2022 Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... December 12, 2020 No Improvement in OS with Adding Palbociclib to Letrozole for the... January 24, 2024 Load more HOT NEWS Research with integrity – why building networks is vital for integrity 3 ways we’re helping teenagers and young adults with cancer Bus Driver Wears Different Costume Each Day To Make Kids Smile... Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To...
